ArticleTargeted oncology2026

First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies.

Albiruni Razak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.